Sign In
Buy SLN
$6.41
+0.0400 (+0.628%)
At Close: Jun 03, 2026
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
02:30pm, Monday, 18'th Nov 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming pe
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
09:13am, Sunday, 08'th Sep 2024
Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main val
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
02:18pm, Thursday, 05'th Sep 2024
Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
08:00am, Tuesday, 27'th Aug 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transform
The 3 Best Gene Editing Stocks to Buy in August 2024
09:00am, Wednesday, 07'th Aug 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
06:08am, Thursday, 25'th Jul 2024
Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unava
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
11:11am, Friday, 12'th Jul 2024
Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
08:30am, Monday, 24'th Jun 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transform
Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results
02:31pm, Friday, 21'st Jun 2024
Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
07:30am, Thursday, 20'th Jun 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transform
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
08:30am, Thursday, 30'th May 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transform
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
08:30am, Thursday, 16'th May 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transform
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
08:30am, Tuesday, 30'th Apr 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transform
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
08:30am, Monday, 29'th Apr 2024
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transfor
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
09:26am, Friday, 12'th Apr 2024
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in
